PRMT1 is an important factor for medulloblastoma cell proliferation and survival
Aberrant expression of protein arginine methyltransferases (PRMTs) has been implicated in a number of brain tumors, but the role of PRMT1 in medulloblastoma, the most common malignant pediatric brain tumor, remains unexplored. By examining the publicly available databases of pediatric brain tumor co...
Saved in:
| Published in | Biochemistry and biophysics reports Vol. 32; p. 101364 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.12.2022
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Aberrant expression of protein arginine methyltransferases (PRMTs) has been implicated in a number of brain tumors, but the role of PRMT1 in medulloblastoma, the most common malignant pediatric brain tumor, remains unexplored. By examining the publicly available databases of pediatric brain tumor collection, we found that PRMT1 was predominantly expressed in medulloblastomas across all the pediatric brain tumors and that the high-level expression of PRMT1 correlated with poor survival of medulloblastoma patients. To determine the role of PRMT1 in medulloblastoma cells, we established an inducible knockdown system and demonstrated that PRMT1 depletion decreased medulloblastoma cell proliferation and induced cell apoptosis. Furthermore, the diamidine compounds, previously shown to exhibit selective PRMT1 inhibition, suppressed medulloblastoma cell viability in a dose-dependent manner. Finally, we observed induction of medulloblastoma cell apoptosis by the potent diamidine compounds at low micromolar concentrations. Together, our results suggest that PRMT1 could be an actionable therapeutic target in medulloblastoma.
•PRMT1 is predominantly expressed in medulloblastoma among pediatric brain tumors and correlates with poor patient survival.•PRMT1 knockdown suppressed medulloblastoma cell growth and induced apoptosis.•The diamidine compounds reduced medulloblastoma cell viability and induced medulloblastoma cell apoptosis. |
|---|---|
| AbstractList | Aberrant expression of protein arginine methyltransferases (PRMTs) has been implicated in a number of brain tumors, but the role of PRMT1 in medulloblastoma, the most common malignant pediatric brain tumor, remains unexplored. By examining the publicly available databases of pediatric brain tumor collection, we found that PRMT1 was predominantly expressed in medulloblastomas across all the pediatric brain tumors and that the high-level expression of PRMT1 correlated with poor survival of medulloblastoma patients. To determine the role of PRMT1 in medulloblastoma cells, we established an inducible knockdown system and demonstrated that PRMT1 depletion decreased medulloblastoma cell proliferation and induced cell apoptosis. Furthermore, the diamidine compounds, previously shown to exhibit selective PRMT1 inhibition, suppressed medulloblastoma cell viability in a dose-dependent manner. Finally, we observed induction of medulloblastoma cell apoptosis by the potent diamidine compounds at low micromolar concentrations. Together, our results suggest that PRMT1 could be an actionable therapeutic target in medulloblastoma.Aberrant expression of protein arginine methyltransferases (PRMTs) has been implicated in a number of brain tumors, but the role of PRMT1 in medulloblastoma, the most common malignant pediatric brain tumor, remains unexplored. By examining the publicly available databases of pediatric brain tumor collection, we found that PRMT1 was predominantly expressed in medulloblastomas across all the pediatric brain tumors and that the high-level expression of PRMT1 correlated with poor survival of medulloblastoma patients. To determine the role of PRMT1 in medulloblastoma cells, we established an inducible knockdown system and demonstrated that PRMT1 depletion decreased medulloblastoma cell proliferation and induced cell apoptosis. Furthermore, the diamidine compounds, previously shown to exhibit selective PRMT1 inhibition, suppressed medulloblastoma cell viability in a dose-dependent manner. Finally, we observed induction of medulloblastoma cell apoptosis by the potent diamidine compounds at low micromolar concentrations. Together, our results suggest that PRMT1 could be an actionable therapeutic target in medulloblastoma. Aberrant expression of protein arginine methyltransferases (PRMTs) has been implicated in a number of brain tumors, but the role of PRMT1 in medulloblastoma, the most common malignant pediatric brain tumor, remains unexplored By examining the publicly available databases of pediatric brain tumor collection, we found that PRMT1 was predominantly expressed in medulloblastomas across all the pediatric brain tumors and that the high-level expression of PRMT1 correlated with poor survival of medulloblastoma patients. To determine the role of PRMT1 in medulloblastoma cells, we established an inducible knockdown system and demonstrated that PRMT1 depletion decreased medulloblastoma cell proliferation and induced cell apoptosis. Furthermore, the diamidine compounds, previously shown to exhibit selective PRMT1 inhibition, suppressed medulloblastoma cell viability in a dose-dependent manner. Finally, we observed induction of medulloblastoma cell apoptosis by the potent diamidine compounds at low micromolar concentrations. Together, our results suggest that PRMT1 could be an actionable therapeutic target in medulloblastoma. Aberrant expression of protein arginine methyltransferases (PRMTs) has been implicated in a number of brain tumors, but the role of PRMT1 in medulloblastoma, the most common malignant pediatric brain tumor, remains unexplored. By examining the publicly available databases of pediatric brain tumor collection, we found that PRMT1 was predominantly expressed in medulloblastomas across all the pediatric brain tumors and that the high-level expression of PRMT1 correlated with poor survival of medulloblastoma patients. To determine the role of PRMT1 in medulloblastoma cells, we established an inducible knockdown system and demonstrated that PRMT1 depletion decreased medulloblastoma cell proliferation and induced cell apoptosis. Furthermore, the diamidine compounds, previously shown to exhibit selective PRMT1 inhibition, suppressed medulloblastoma cell viability in a dose-dependent manner. Finally, we observed induction of medulloblastoma cell apoptosis by the potent diamidine compounds at low micromolar concentrations. Together, our results suggest that PRMT1 could be an actionable therapeutic target in medulloblastoma. •PRMT1 is predominantly expressed in medulloblastoma among pediatric brain tumors and correlates with poor patient survival.•PRMT1 knockdown suppressed medulloblastoma cell growth and induced apoptosis.•The diamidine compounds reduced medulloblastoma cell viability and induced medulloblastoma cell apoptosis. Aberrant expression of protein arginine methyltransferases (PRMTs) has been implicated in a number of brain tumors, but the role of PRMT1 in medulloblastoma, the most common malignant pediatric brain tumor, remains unexplored. By examining the publicly available databases of pediatric brain tumor collection, we found that PRMT1 was predominantly expressed in medulloblastomas across all the pediatric brain tumors and that the high-level expression of PRMT1 correlated with poor survival of medulloblastoma patients. To determine the role of PRMT1 in medulloblastoma cells, we established an inducible knockdown system and demonstrated that PRMT1 depletion decreased medulloblastoma cell proliferation and induced cell apoptosis. Furthermore, the diamidine compounds, previously shown to exhibit selective PRMT1 inhibition, suppressed medulloblastoma cell viability in a dose-dependent manner. Finally, we observed induction of medulloblastoma cell apoptosis by the potent diamidine compounds at low micromolar concentrations. Together, our results suggest that PRMT1 could be an actionable therapeutic target in medulloblastoma. Aberrant expression of protein arginine methyltransferases (PRMTs) has been implicated in a number of brain tumors, but the role of PRMT1 in medulloblastoma, the most common malignant pediatric brain tumor, remains unexplored . By examining the publicly available databases of pediatric brain tumor collection, we found that PRMT1 was predominantly expressed in medulloblastomas across all the pediatric brain tumors and that the high-level expression of PRMT1 correlated with poor survival of medulloblastoma patients. To determine the role of PRMT1 in medulloblastoma cells, we established an inducible knockdown system and demonstrated that PRMT1 depletion decreased medulloblastoma cell proliferation and induced cell apoptosis. Furthermore, the diamidine compounds, previously shown to exhibit selective PRMT1 inhibition, suppressed medulloblastoma cell viability in a dose-dependent manner. Finally, we observed induction of medulloblastoma cell apoptosis by the potent diamidine compounds at low micromolar concentrations. Together, our results suggest that PRMT1 could be an actionable therapeutic target in medulloblastoma. • PRMT1 is predominantly expressed in medulloblastoma among pediatric brain tumors and correlates with poor patient survival. • PRMT1 knockdown suppressed medulloblastoma cell growth and induced apoptosis. • The diamidine compounds reduced medulloblastoma cell viability and induced medulloblastoma cell apoptosis. |
| ArticleNumber | 101364 |
| Author | Li, Zhi-Jie Lebedev, Timofey Zheng, Y. George Hua, Zhong-Yan Lin, Cheng-Han Li, Xing-Guo He, Miao Yang, Jer-Yen Gu, Xiao |
| Author_xml | – sequence: 1 givenname: Xiao surname: Gu fullname: Gu, Xiao email: xiao_gu@urmc.rochester.edu organization: Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA – sequence: 2 givenname: Miao surname: He fullname: He, Miao email: miaom_he@urmc.rochester.edu organization: Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA – sequence: 3 givenname: Timofey surname: Lebedev fullname: Lebedev, Timofey email: lebedevtd@gmail.com organization: Department of Cancer Cell Biology, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia – sequence: 4 givenname: Cheng-Han surname: Lin fullname: Lin, Cheng-Han email: billy1100625@gmail.com organization: Research Center for Cancer Biology, Graduate Institute of Biomedical Sciences, Institute of Biochemistry and Molecular Biology, China Medical University, Taichung City, 406040, Taiwan – sequence: 5 givenname: Zhong-Yan surname: Hua fullname: Hua, Zhong-Yan email: huazhongyan123@hotmail.com organization: Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA – sequence: 6 givenname: Y. George surname: Zheng fullname: Zheng, Y. George email: yzheng@uga.edu organization: Department of Pharmaceutical and Biochemical Sciences, College of Pharmacy, University of Georgia, Athens, GA, USA – sequence: 7 givenname: Zhi-Jie surname: Li fullname: Li, Zhi-Jie email: lizhijie68@hotmail.com organization: Liaoning Key Laboratory of Research and Application of Animal Models for Environmental and Metabolic Diseases, Medical Research Center, Shengjing Hospital of China Medical University, Shenyang, China – sequence: 8 givenname: Jer-Yen surname: Yang fullname: Yang, Jer-Yen email: jyyang@cmu.edu.tw organization: Research Center for Cancer Biology, Graduate Institute of Biomedical Sciences, Institute of Biochemistry and Molecular Biology, China Medical University, Taichung City, 406040, Taiwan – sequence: 9 givenname: Xing-Guo surname: Li fullname: Li, Xing-Guo email: xli@mail.cmu.edu.tw organization: Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36237442$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl1rHSEQhqWkNB_NLyiUvezNORldddeLFkpok0BKQ0mvxVU39eCuW3UP9N_XczYJSS4CijLO-wzOvMfoYAyjRegDhjUGzM82666LdloTIGQXqTl9g44IBbZiLbQHT-6H6DSlDQBgRlpG-Dt0WHNSN5SSI3Rz8-vHLa5cqtRYuWEKMasxV73SOcSqL3uwZvY-dF6lHAZVaet9NcXgXW-jyi6MRWqqNMet2yr_Hr3tlU_29P48Qb-_f7s9v1xd_7y4Ov96vdKMsLzSwghNwWhqCTDARINW0GEsoCzO-q5RphZEMYJNQ_u6bTQVujfU4FY1vD5BVwvXBLWRU3SDiv9kUE7uAyHeSRWz095KxjlvTIFTjGnTQscxcGVsDa3VjDeF9WVhTXNXvqvtmKPyz6DPX0b3R96FrRSMAQdaAJ_uATH8nW3KcnBp1yg12jAnSRrCsGBCQEn9-LTWY5GHkZQEsSToGFKKtpfa5X2fS2nnJQa5c4DcyL0D5M4BcnFA0dYvtA_411WfF5Ut89o6G2XSzo7aGhetzqWh7lX9f4Lxyg8 |
| CitedBy_id | crossref_primary_10_3389_fonc_2024_1489164 |
| Cites_doi | 10.1038/s41572-019-0063-6 10.1016/j.neo.2017.05.002 10.1007/s00018-019-03145-x 10.1186/s13046-019-1064-8 10.3390/cells10010124 10.1093/nar/gkz200 10.1038/s41389-020-0237-9 10.1038/s41598-019-52291-6 10.1016/j.ccell.2019.05.014 10.5483/BMBRep.2012.45.8.022 10.1021/acschemneuro.7b00258 10.1016/j.jbiotec.2016.07.028 10.3390/ijms22052622 10.1186/s12885-019-6291-z 10.3389/fonc.2020.00226 10.1039/C6MD00573J 10.1016/j.ccell.2019.07.003 10.1038/s41580-019-0155-x |
| ContentType | Journal Article |
| Copyright | 2022 The Authors 2022 The Authors. Published by Elsevier B.V. 2022 The Authors. Published by Elsevier B.V. 2022 |
| Copyright_xml | – notice: 2022 The Authors – notice: 2022 The Authors. Published by Elsevier B.V. – notice: 2022 The Authors. Published by Elsevier B.V. 2022 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.bbrep.2022.101364 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ: Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry |
| EISSN | 2405-5808 |
| ExternalDocumentID | oai_doaj_org_article_56667d0b14114780b6106ade308ec567 PMC9550604 36237442 10_1016_j_bbrep_2022_101364 S2405580822001649 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: R01 GM126154 |
| GroupedDBID | 0R~ 0SF 457 53G 5VS 6I. AACTN AAEDW AAFTH AAFWJ AALRI AAXUO ABMAC ACGFS ADBBV ADEZE AEXQZ AFPKN AFTJW AGHFR AITUG ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BCNDV EBS EJD FDB GROUPED_DOAJ HYE IPNFZ KQ8 M~E NCXOZ O9- OK1 RIG ROL RPM SSZ AAYWO AAYXX ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AIGII AKBMS AKRWK AKYEP APXCP CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c525t-c9d9c40dc4e205012c0ca0b119019065fb7ad392a521d74f387c49cfd4d18a763 |
| IEDL.DBID | DOA |
| ISSN | 2405-5808 |
| IngestDate | Wed Aug 27 01:25:07 EDT 2025 Thu Aug 21 18:39:22 EDT 2025 Fri Jul 11 12:12:58 EDT 2025 Thu Apr 03 07:02:57 EDT 2025 Thu Apr 24 23:07:36 EDT 2025 Tue Jul 01 03:08:23 EDT 2025 Tue Jul 25 20:59:46 EDT 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | PRMT1 inhibitors Diamidine compounds Dox PRMT1 shRNA Medulloblastoma Dox, Doxycycline shRNA, short hairpin RNA PRMT1, protein arginine methyltransferase 1 |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c525t-c9d9c40dc4e205012c0ca0b119019065fb7ad392a521d74f387c49cfd4d18a763 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doaj.org/article/56667d0b14114780b6106ade308ec567 |
| PMID | 36237442 |
| PQID | 2725195990 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_56667d0b14114780b6106ade308ec567 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9550604 proquest_miscellaneous_2725195990 pubmed_primary_36237442 crossref_citationtrail_10_1016_j_bbrep_2022_101364 crossref_primary_10_1016_j_bbrep_2022_101364 elsevier_sciencedirect_doi_10_1016_j_bbrep_2022_101364 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-12-01 |
| PublicationDateYYYYMMDD | 2022-12-01 |
| PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Biochemistry and biophysics reports |
| PublicationTitleAlternate | Biochem Biophys Rep |
| PublicationYear | 2022 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Chandrashekar, Bashel, Balasubramanya, Creighton, Rodriguez, Chakravarthi, Varambally (bib6) 2017 Aug; 19 Hansen, Li, Zheng, Lotta, Dedhe, Schor (bib13) 2017; 8 Ivanov, Coyle, Walker, Grabowska (bib10) 2016 Oct 20; 236 Gao, Zhang, Villarreal, He, Su, Bedford, Moh, Shen, Shi, Bedford, Xu (bib14) 2019 Jun 4; 47 Li, An, Xu, Lin, Su, Liu (bib18) 2019; 38 Ceccarelli, D'Andrea, Micheli, Tirone (bib5) 2020 Mar 13; 10 Northcott, Robinson, Kratz, Mabbott, Pomeroy, Clifford, Rutkowski, Ellison, Malkin, Taylor, Gajjar, Pfister (bib2) 2019 Feb 14; 5 Wang, Tan, Yang, Yin, Yuan, Qiang, Peng (bib9) 2012; 45 Chaturvedi, Mahapatra, Kesherwani, Kling, Shukla, Ray, Kanchan, Perumal, McGuire, Sharp, Joshi, Coulter (bib3) 2019 Nov 6; 19 Tewary, Zheng, Ho (bib8) 2019; 76 Favia, Salvatori, Nanni, Iwamoto-Stohl, Valente, Mai, Scagnoli, Fontanella, Totta, Nasi, Illi (bib17) 2019 Nov 4; 9 Ryu, Kim, Son, Min, Kim, Han (bib19) 2019; 41 Fedoriw, Rajapurkar, O'Brien, Gerhart, Mitchell, Adams, Rioux, Lingaraj, Ribich, Pappalardi, Shah, Laraio, Liu, Butticello, Carpenter, Creasy, Korenchuk, McCabe, McHugh, Nagarajan, Wagner, Zappacosta, Annan, Concha, Thomas, Hart, Smith, Copeland, Moyer, Campbell, Stickland, Mills, Jacques-O'Hagan, Allain, Johnston, Raimondi, Porter Scott, Waters, Swinger, Boriack-Sjodin, Riera, Shapiro, Chesworth, Prinjha, Kruger, Barbash, Mohammad (bib16) 2019 Jul 8; 36 Hua, Hansen, He, Dai, Choi, Fulton, Lloyd, Szemes, Sen, Ding, Angelastro, Fei, Li, Wu, Yang, Malik, Bao, George Zheng, Liu, Schor, Li, Li (bib4) 2020 May 15; 9 Guccione, Richard (bib11) 2019 Oct; 20 Zhang, Qian, Yan, He, Jassim, Ivanov, Zheng (bib12) 2017; 8 Fong, Pignata, Goy, Kawabata, Lee, Koh, Musiani, Massignani, Kotini, Penson, Wun, Shen, Schwarz, Low, Rialdi, Ki, Wollmann, Mzoughi, Gay, Thompson, Hart, Barbash, Luciani, Szewczyk, Wouters, Delwel, Papapetrou, Barsyte-Lovejoy, Arrowsmith, Minden, Jin, Melnick, Bonaldi, Abdel-Wahab, Guccione (bib15) 2019 Aug 12; 36 Bryant, Heiss, Banasavadi-Siddegowda (bib1) 2021 Jan 11; 10 Bartha, Győrffy (bib7) 2021 Mar 5; 22 Northcott (10.1016/j.bbrep.2022.101364_bib2) 2019; 5 Chaturvedi (10.1016/j.bbrep.2022.101364_bib3) 2019; 19 Zhang (10.1016/j.bbrep.2022.101364_bib12) 2017; 8 Ceccarelli (10.1016/j.bbrep.2022.101364_bib5) 2020; 10 Tewary (10.1016/j.bbrep.2022.101364_bib8) 2019; 76 Gao (10.1016/j.bbrep.2022.101364_bib14) 2019; 47 Guccione (10.1016/j.bbrep.2022.101364_bib11) 2019; 20 Favia (10.1016/j.bbrep.2022.101364_bib17) 2019; 9 Hua (10.1016/j.bbrep.2022.101364_bib4) 2020; 9 Fedoriw (10.1016/j.bbrep.2022.101364_bib16) 2019; 36 Wang (10.1016/j.bbrep.2022.101364_bib9) 2012; 45 Li (10.1016/j.bbrep.2022.101364_bib18) 2019; 38 Bartha (10.1016/j.bbrep.2022.101364_bib7) 2021; 22 Ivanov (10.1016/j.bbrep.2022.101364_bib10) 2016; 236 Hansen (10.1016/j.bbrep.2022.101364_bib13) 2017; 8 Fong (10.1016/j.bbrep.2022.101364_bib15) 2019; 36 Chandrashekar (10.1016/j.bbrep.2022.101364_bib6) 2017; 19 Ryu (10.1016/j.bbrep.2022.101364_bib19) 2019; 41 Bryant (10.1016/j.bbrep.2022.101364_bib1) 2021; 10 |
| References_xml | – volume: 9 start-page: 50 year: 2020 May 15 ident: bib4 article-title: PRMT1 promotes neuroblastoma cell survival through ATF5 publication-title: Oncogenesis – volume: 5 start-page: 11 year: 2019 Feb 14 ident: bib2 publication-title: Medulloblastoma. Nat Rev Dis Primers. – volume: 45 start-page: 470 year: 2012 end-page: 475 ident: bib9 article-title: The role of protein arginine-methyltransferase 1 in gliomagenesis publication-title: BMB Rep. – volume: 36 start-page: 100 year: 2019 Jul 8 end-page: 114.e25 ident: bib16 article-title: Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss publication-title: Cancer Cell – volume: 10 start-page: 226 year: 2020 Mar 13 ident: bib5 article-title: Deletion of Btg1 induces prmt1-dependent apoptosis and increased stemness in shh-type medulloblastoma cells without affecting tumor frequency publication-title: Front. Oncol. – volume: 47 start-page: 5038 year: 2019 Jun 4 end-page: 5048 ident: bib14 article-title: PRMT1 loss sensitizes cells to PRMT5 inhibition publication-title: Nucleic Acids Res. – volume: 10 start-page: 124 year: 2021 Jan 11 ident: bib1 article-title: Arginine methylation in brain tumors: tumor biology and therapeutic strategies publication-title: Cells – volume: 236 start-page: 10 year: 2016 Oct 20 end-page: 25 ident: bib10 article-title: In vitro models of medulloblastoma: choosing the right tool for the job publication-title: J. Biotechnol. – volume: 36 start-page: 194 year: 2019 Aug 12 end-page: 209 ident: bib15 article-title: Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation publication-title: Cancer Cell – volume: 19 start-page: 1056 year: 2019 Nov 6 ident: bib3 article-title: Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma publication-title: BMC Cancer – volume: 8 start-page: 2118 year: 2017 end-page: 2123 ident: bib13 article-title: Using chemistry to target neuroblastoma publication-title: ACS Chem. Neurosci. – volume: 20 start-page: 642 year: 2019 Oct end-page: 657 ident: bib11 article-title: The regulation, functions and clinical relevance of arginine methylation publication-title: Nat. Rev. Mol. Cell Biol. – volume: 38 start-page: 64 year: 2019 ident: bib18 article-title: The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLAR(L) in human lung cancer cells publication-title: J. Exp. Clin. Cancer Res. – volume: 8 start-page: 440 year: 2017 end-page: 444 ident: bib12 article-title: Discovery of decamidine as a new and potent PRMT1 inhibitor publication-title: Medchemcomm – volume: 19 start-page: 649 year: 2017 Aug end-page: 658 ident: bib6 article-title: UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses publication-title: Neoplasia – volume: 76 start-page: 2917 year: 2019 end-page: 2932 ident: bib8 article-title: Protein arginine methyltransferases: insights into the enzyme structure and mechanism at the atomic level publication-title: Cell. Mol. Life Sci. – volume: 22 start-page: 2622 year: 2021 Mar 5 ident: bib7 article-title: TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues publication-title: Int. J. Mol. Sci. – volume: 9 year: 2019 Nov 4 ident: bib17 article-title: The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells publication-title: Sci. Rep. – volume: 41 start-page: 1691 year: 2019 end-page: 1699 ident: bib19 article-title: Downregulation of PRMT1, a histone arginine methyltransferase, by sodium propionate induces cell apoptosis in colon cancer publication-title: Oncol. Rep. – volume: 5 start-page: 11 issue: 1 year: 2019 ident: 10.1016/j.bbrep.2022.101364_bib2 publication-title: Medulloblastoma. Nat Rev Dis Primers. doi: 10.1038/s41572-019-0063-6 – volume: 19 start-page: 649 issue: 8 year: 2017 ident: 10.1016/j.bbrep.2022.101364_bib6 article-title: UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses publication-title: Neoplasia doi: 10.1016/j.neo.2017.05.002 – volume: 41 start-page: 1691 year: 2019 ident: 10.1016/j.bbrep.2022.101364_bib19 article-title: Downregulation of PRMT1, a histone arginine methyltransferase, by sodium propionate induces cell apoptosis in colon cancer publication-title: Oncol. Rep. – volume: 76 start-page: 2917 year: 2019 ident: 10.1016/j.bbrep.2022.101364_bib8 article-title: Protein arginine methyltransferases: insights into the enzyme structure and mechanism at the atomic level publication-title: Cell. Mol. Life Sci. doi: 10.1007/s00018-019-03145-x – volume: 38 start-page: 64 year: 2019 ident: 10.1016/j.bbrep.2022.101364_bib18 article-title: The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLAR(L) in human lung cancer cells publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-019-1064-8 – volume: 10 start-page: 124 issue: 1 year: 2021 ident: 10.1016/j.bbrep.2022.101364_bib1 article-title: Arginine methylation in brain tumors: tumor biology and therapeutic strategies publication-title: Cells doi: 10.3390/cells10010124 – volume: 47 start-page: 5038 issue: 10 year: 2019 ident: 10.1016/j.bbrep.2022.101364_bib14 article-title: PRMT1 loss sensitizes cells to PRMT5 inhibition publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkz200 – volume: 9 start-page: 50 issue: 5 year: 2020 ident: 10.1016/j.bbrep.2022.101364_bib4 article-title: PRMT1 promotes neuroblastoma cell survival through ATF5 publication-title: Oncogenesis doi: 10.1038/s41389-020-0237-9 – volume: 9 issue: 1 year: 2019 ident: 10.1016/j.bbrep.2022.101364_bib17 article-title: The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells publication-title: Sci. Rep. doi: 10.1038/s41598-019-52291-6 – volume: 36 start-page: 100 issue: 1 year: 2019 ident: 10.1016/j.bbrep.2022.101364_bib16 article-title: Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.05.014 – volume: 45 start-page: 470 year: 2012 ident: 10.1016/j.bbrep.2022.101364_bib9 article-title: The role of protein arginine-methyltransferase 1 in gliomagenesis publication-title: BMB Rep. doi: 10.5483/BMBRep.2012.45.8.022 – volume: 8 start-page: 2118 issue: 10 year: 2017 ident: 10.1016/j.bbrep.2022.101364_bib13 article-title: Using chemistry to target neuroblastoma publication-title: ACS Chem. Neurosci. doi: 10.1021/acschemneuro.7b00258 – volume: 236 start-page: 10 year: 2016 ident: 10.1016/j.bbrep.2022.101364_bib10 article-title: In vitro models of medulloblastoma: choosing the right tool for the job publication-title: J. Biotechnol. doi: 10.1016/j.jbiotec.2016.07.028 – volume: 22 start-page: 2622 issue: 5 year: 2021 ident: 10.1016/j.bbrep.2022.101364_bib7 article-title: TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms22052622 – volume: 19 start-page: 1056 issue: 1 year: 2019 ident: 10.1016/j.bbrep.2022.101364_bib3 article-title: Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma publication-title: BMC Cancer doi: 10.1186/s12885-019-6291-z – volume: 10 start-page: 226 year: 2020 ident: 10.1016/j.bbrep.2022.101364_bib5 article-title: Deletion of Btg1 induces prmt1-dependent apoptosis and increased stemness in shh-type medulloblastoma cells without affecting tumor frequency publication-title: Front. Oncol. doi: 10.3389/fonc.2020.00226 – volume: 8 start-page: 440 issue: 2 year: 2017 ident: 10.1016/j.bbrep.2022.101364_bib12 article-title: Discovery of decamidine as a new and potent PRMT1 inhibitor publication-title: Medchemcomm doi: 10.1039/C6MD00573J – volume: 36 start-page: 194 issue: 2 year: 2019 ident: 10.1016/j.bbrep.2022.101364_bib15 article-title: Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.07.003 – volume: 20 start-page: 642 issue: 10 year: 2019 ident: 10.1016/j.bbrep.2022.101364_bib11 article-title: The regulation, functions and clinical relevance of arginine methylation publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/s41580-019-0155-x |
| SSID | ssj0001528526 |
| Score | 2.2631211 |
| Snippet | Aberrant expression of protein arginine methyltransferases (PRMTs) has been implicated in a number of brain tumors, but the role of PRMT1 in medulloblastoma,... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 101364 |
| SubjectTerms | Diamidine compounds Medulloblastoma PRMT1 PRMT1 inhibitors |
| Title | PRMT1 is an important factor for medulloblastoma cell proliferation and survival |
| URI | https://dx.doi.org/10.1016/j.bbrep.2022.101364 https://www.ncbi.nlm.nih.gov/pubmed/36237442 https://www.proquest.com/docview/2725195990 https://pubmed.ncbi.nlm.nih.gov/PMC9550604 https://doaj.org/article/56667d0b14114780b6106ade308ec567 |
| Volume | 32 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hcoAL4k0oVEbiSITXsWP7WCqqigpUVa3ozfIrYhHNVmz2_3dsJ6sNSOXCJYoS28k84vkcjb8BeO-8bgONrhYLPPDg2xpReKytUEyGoGQoWb7f2pNL_uVKXO2U-ko5YYUeuCjuI8KNFju4BUfkLhV1GO9bG2JDVfSizfvIMebtLKbK_mCmRK61hhFL1EJRNVEO5eQuh-vNxFbJWLrStHwWljJ7_yw6_Y0-_0yi3IlKx4_h0QgnyWER4wnci_1TeHA0VXF7Bmdn518vFmS5JrYny-uMtvuBlDI7BBErwcFxGbpyCKOH1bUl6Vc-uUnFfLpY3AO7BrLe4KSCbvkcLo8_Xxyd1GMVhdoLJoba66A9p8HzyKjAeOSpt6jPhAQ0ApDOSRsQJVkM5EHyrlHSc-27wMNCWZx-XsBev-rjKyBRdVaxIIPvHO9ccAJPddN0PlCpqaqATUo0fqQYT5Uufpkpl-ynyZo3SfOmaL6CD9tON4Vh4-7mn5J1tk0TPXa-gE5jRqcx_3KaCtrJtmZEGgVB4FDLu5_-bvIEg4ZMFrF9XG3WhkmWiXo0reBl8YztOyJIaCTnrAI585mZEPM7_fJH5vrWIjNAvv4fUu_DwyRKScZ5A3vD7018i5BqcAdw__D0_PvpQf6KbgEDEx3d |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PRMT1+is+an+important+factor+for+medulloblastoma+cell+proliferation+and+survival&rft.jtitle=Biochemistry+and+biophysics+reports&rft.au=Xiao+Gu&rft.au=Miao+He&rft.au=Timofey+Lebedev&rft.au=Cheng-Han+Lin&rft.date=2022-12-01&rft.pub=Elsevier&rft.issn=2405-5808&rft.eissn=2405-5808&rft.volume=32&rft.spage=101364&rft_id=info:doi/10.1016%2Fj.bbrep.2022.101364&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_56667d0b14114780b6106ade308ec567 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2405-5808&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2405-5808&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2405-5808&client=summon |